Advertisement

Immunoglobulin-bound lipoproteins (Ig-Lp) as markers of familial hypercholesterolemia, xanthomatosis and atherosclerosis

  • J.L. Beaumont
    Correspondence
    Correspondence to: Dr. J.L. Beaumont, INSERM U. 32, Hôpital Henri Mondor, F-94010 Creteil, France.
    Affiliations
    INSERM U. 32 and Association Claude Bernard, Centre de Recherches sur les Maladies de Artères, Hôpital Henri Mondor, F-94010 Creteil, France
    Search for articles by this author
  • F. Doucet
    Affiliations
    INSERM U. 32 and Association Claude Bernard, Centre de Recherches sur les Maladies de Artères, Hôpital Henri Mondor, F-94010 Creteil, France
    Search for articles by this author
  • P. Vivier
    Affiliations
    INSERM U. 32 and Association Claude Bernard, Centre de Recherches sur les Maladies de Artères, Hôpital Henri Mondor, F-94010 Creteil, France
    Search for articles by this author
  • M. Antonucci
    Affiliations
    INSERM U. 32 and Association Claude Bernard, Centre de Recherches sur les Maladies de Artères, Hôpital Henri Mondor, F-94010 Creteil, France
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      In autoimmune hyper- or dislipidemia secondary to a monoclonal antilipoprotein gammapathy, immunoglobulin-lipoprotein (Ig-Lp) complexes are found in the circulating blood. In order to determine their possible significance in common types of hyperlipidemia we compared the Ig-Lp content of sera from 98 healthy blood donors and 155 outpatients from a Lipid Clinic, including 91 cases of hypercholesterolemia (55 familial and 36 non-familial), 15 cases of hypertriglyceridemia, 20 cases of mixed hyperlipidemia and 29 miscellaneous cases. Detection of the Ig-Lp was performed by an ELISA technique with polyclonal affinity purified anti-LDL + HDL as capture antibodies and peroxidase-labeled anti-Ig antibodies specific for IgA, IgG, IgM heavy chains as indicators. Two cases of monoclonal gammapathy (one IgA K and one IgG L) with dislipidemia served as positive controls for the test. IgG, IgA and IgM Lp were found in the sera of the blood donors, in very small quantities when compared with the monoclonal gammapathy cases. All three types of Ig-Lp were also found in the different hyperlipidemic populations studied. When blood donors were compared to hyperlipidemic patients, no difference was observed for IgG Lp. A significant increase in IgM Lp was found in patients with familial hypercholesterolemia (P < 0.01). An increase in IgA Lp was also found in hypercholesterolemia, familial or not (P < 0.01), and in patients with corneal arcus (P < 0.0001), ischaemic disease (P < 0.01), tendon xanthomas (P < 0.05) or xanthelasma (P < 0.05). Furthermore, in a group of 18 paired parents from 9 different families, positive interparent correlations were found for IgM Lp (r = 0.78; P = 0.013) and IgG Lp (r = 0.69; P = 0.038). Therefore IgM Lp may be markers for subpopulations of familial hypercholesterolemia, and IgA Lp markers for the risk of atherosclerotic ischemic disease and deposition of lipids in the cornea. It may be (1) that natural clones of autoanti-lipoprotein antibodies are responsible for the minute quantities of Ig-Lp found in normal people; (2) that the marked development of one of these clones is the cause of autoimmune hyper- or dyslipidemia and xanthomatosis associated with monoclonal gammapathy; (3) that the limited development of a clone produces the Ig-Lp particles found in hypercholesterolemic patients; (4) that there are types of Ig-Lp particles (IgA Lp) that may be harmful for tissues independently of hypercholesterolemia.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldstein J.L.
        • Brown M.S.
        The low-density lipoprotein pathway and its relation to atherosclerosis.
        Annu. Rev. Biochem. 1977; 46: 897
        • Goldstein J.L.
        • Ho Y.K.
        • Basu S.K.
        • Brown M.S.
        Binding site on macrophages that mediate uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.
        in: 3rd edn. Proc. Natl. Acad. Sci. USA. 76. 1979: 33
        • Van der Westhuyzen D.R.
        • Coetzee G.M.
        • Demazius I.P.C.
        • Harley E.M.
        • Gevers W.
        • Baker S.G.
        • Seftel M.C.
        Low density lipoprotein receptor mutations in South African homozygous familial hypercholesterolemic patients.
        Arteriosclerosis. 1984; 4: 238
        • Brown M.S.
        • Basu S.K.
        • Falk J.R.
        • Ho Y.K.
        • Goldstein J.L.
        The scavenger cell pathway for lipoprotein degradation.
        J. Supramol. Struct. 1980; 13: 67
        • Kita T.
        • Yokode M.
        • Watanabe Y.
        • Narumiya S.
        • Kawai C.
        Stimulation of cholesteryl ester synthesis in mouse peritoneal macrophage by cholesterol rich very low density lipoproteins from the Watanabe heritable hyperlipidemic rabbit, an animal model of familial hypercholesterolemia.
        J. Clin. Invest. 1986; 77: 1460
        • Carew T.E.
        • Schwenke D.C.
        • Steinberg D.
        Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxydants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.
        in: 3rd edn. Proc. Natl. Sci. USA. 84. 1987: 7725
        • Beaumont J.L.
        L'hyperlipidémie à auto-anticorps antibeta-lipoprotéine. Une nouvelle entité pathologique.
        C.R. Acad. Sci. Paris. 1965; 861: 4563
        • Beaumont J.L.
        • Lorenzelli L.
        L'auto-anticorps antilipoprotéine (anti-Pg) du gamma-A myélome avec hyperlipidémie. Méthode d'isolement et de purification à partir des complexes circulants.
        Ann. Biol. Clin. 1967; 25: 1955
        • Beaumont J.L.
        • Beaumont V.
        Autoimmune hyperlipidemia.
        Atherosclerosis. 1977; 26: 405
        • Kilgore L.L.
        • Patterson B.W.
        • Parenti D.M.
        • Fisher W.R.
        Immune complex hyperlipidemia produced by an apoprotein reactive immunoglobulin A paraprotein from a patient with multiple myeloma.
        J. Clin. Invest. 1985; 76: 225
        • Beaumont J.L.
        • Baudet M.F.
        • Dachet C.
        • Beaumont V.
        Autoimmune hyperlipidemia and autoimmune xanthomatosis.
        in: Vth. Int. Symp. Ather., Berlin Springer-Verlag, Berlin1980: 334
        • Berard M.
        • Antonucci M.
        • Beaumont J.L.
        Cytotoxic effect of serum on fibroblasts in one case of normolipodemic plane xanthoma myeloma IgG.
        Atherosclerosis. 1986; 62: 11
        • Beaumont J.L.
        Autoimmune hyperlipidemia. An atherogenic metabolic disease of immune origin.
        Rev. Eur. Et. Clin. Biol. 1970; 15: 1037
        • Thannhauser S.J.
        Lipidoses: disease of the intracellular lipid metabolism.
        in: 3rd edn. Grune and Stratton, New York1958: 360
        • Cohen L.
        • Blaisdell M.D.
        • Djordjevich J.
        • Ormiste V.
        • Dobrilovic L.
        Familial xanthomatosis and hyperlipidemia and myelomatosis.
        Am. J. Med. 1966; 40: 299
        • Lorenzelli-Edouard L.
        • Marie F.
        • Beaumont J.L.
        Antilipoprotein autoimmune hyperlipidemia.
        The IgLp test, Biomedicine. 1980; 33: 160
        • Beaumont J.L.
        • Buxtorf J.C.
        • Lorenzelli-Edouard L.
        Hyperlipoproteinemias, xanthomatosis, immunoglobulins and autoimmune hyperlipidemia.
        Atherosclerosis. 1980; 36: 315
        • Shields J.G.
        • Turner M.W.
        The importance of antibody quality in Sandwich ELISA systems. Evaluation of selected commercial reagents.
        J. Immunol. Methods. 1986; 87: 29
        • Schwartz D.
        Méthodes Statistiques.
        3rd edn. Flammarion, Paris1975
        • Guilbert B.
        • Dighiero G.
        • Avrameas S.
        Naturally occurring antibodies against nine common antigens in normal serum. I. Detection, isolation and characterization.
        J. Immunol. 1982; 128: 2779
        • Freitas A.A.
        • Guilbert B.
        • Holmberg D.
        • Wennerstrom G.
        • Coutinho A.
        • Avrameas S.
        Analysis of autoantibody reactivities in hybridoma collections derived from normal adult BALB/c mice.
        Ann. Inst. Pasteur Immunol. 1986; 137D: 33
        • Cohen I.R.
        • Cooke A.
        Natural antibodies may prevent autoimmune disease.
        Immunol. Today. 1986; 7: 363
        • Dighiero G.
        • Guilbert B.
        • Avrameas S.
        Naturally occurring antibodies against nine common antigens in human sera. II. High incidence of monoclonal Ig exhibiting antibody activity against actin and tubulin and sharing antibody specificities with natural antibodies.
        J. Immunol. 1982; 128: 2788
        • Brinkschmidt T.
        • Heuk C.C.
        • Schlierf G.
        • Bucholz L.
        • Schmidt-Gayk M.
        The association of hyperlipoproteinemia with dysimmunoglobulinemia.
        Atherosclerosis. 1986; 59: 323
        • Dachet C.
        • Baudet M.F.
        • Beaumont J.L.
        Cholesterol synthesis by human fibroblasts in the presence of LDL and anti LDL IgA.
        Biomedicine (Paris). 1979; 31: 80
        • Baudet M.F.
        • Dachet C.
        • Beaumont J.L.
        Interaction between fibroblasts, lipoproteins and three antilipoprotein IgA kappa.
        Clin. Exp. Immunol. 1980; 39: 455
        • Corsini A.
        • Roma P.
        • Sommariva D.
        • Fumagalli R.
        • Catapano A.L.
        Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.
        J. Clin. Invest. 1986; 78: 940
        • Kita T.
        • Beisiegel U.
        • Goldstein J.L.
        • Schneider W.J.
        • Brown M.S.
        Antibody against low density lipoprotein receptor blocks uptake of low density lipoproteins (but not high density lipoproteins) by the surrenal gland of the mouse in vivo.
        J. Biol. Chem. 1981; 256: 4701
        • Beaumont J.L.
        • Richard J.L.
        • Anguera G.
        • Lenegre J.
        La signification clinique du gerontoxon (arc cornéen).
        B.M. Soc. Méd. Hôp. Paris. 1960; 76: 637
        • Winder A.F.
        Factors influencing the variable expression of xanthelasma and corneal arcus in familial hypercholesterolemia.
        Birth Defects Orig. Art. Ser. 1982; 18: 449-462
        • Beaumont J.L.
        • Jacotot B.
        • Beaumont V.
        l'Hyperlipidémie par autoanticorps. Une cause d'atherosclérose.
        Presse Med. 1967; 75: 2315
        • Scebat L.
        • Renais J.
        • Groult N.
        • Iris L.
        • Lenegre J.
        Lésions artérielles produites chez le lapin par des injections de broyat d'aorte de rat.
        Rev. Fr. Et. Clin. Biol. 1966; 11: 806
        • Minick C.R.
        • Murphy G.E.
        Experimental induction of athero-arteriosclerosis by the synergy of allergic injury to arteries and lipid rich diet.
        J. Exp. Med. 1966; 124: 635
        • Robert L.
        • Robert A.M.
        Elastin, elastase and arteriosclerosis.
        in: 2nd edn. Frontiers of Matrix Biology. vol. 8. Karger, Basel1980: 130
        • Beaumont J.L.
        • Beaumont V.
        • Antonucci M.
        Présence d'un autoanticorps anti-beta-lipoprotéines dans le sérum d'un lapin ayant une hyperlipidémie d'immunisation.
        C.R. Acad. Sci. Paris. 1969; 262: 1830
        • Fust G.
        • Szondy E.
        • Szekeley J.
        • Nanai I.
        • Gero S.
        Studies on the occurrence of circulating immune complexes in vascular diseases.
        Atherosclerosis. 1978; 29: 181
        • Szondy E.
        • Horwath M.
        • Mezey Z.
        • Szekeley J.
        • Lendyel E.
        • Fust G.
        • Gero S.
        Free and complexed antilipoprotein antibodies in vascular diseases.
        Atherosclerosis. 1983; 49: 69
        • Hollander W.
        • Lazzari A.
        • Fransblau C.
        Circulating immune complex in the cholesterol fed cynomolgus monkey.
        in: 40th Am. Council Atheroscl., Dallas, TX, 19862nd edn. Arteriosclerosis. 6. 1986: 525a
        • Klimov A.N.
        • Denisenko A.V.
        • Popov A.V.
        • Nagornev V.A.
        • Pieskov V.M.
        • Vinogradov A.G.
        • Demisenko T.V.
        • Magracheva E.Ya.
        • Kheifes G.M.
        • Kuznetzov A.S.
        Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation.
        Atherosclerosis. 1985; 58: 1
        • Orekhov A.N.
        • Tertov V.V.
        • Pokrovsky S.N.
        • Adamova I.Y.
        • Martsenyuk O.N.
        • Lyakishev A.A.
        • Smirnov V.N.
        Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for a non-lipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination.
        Circ. Res. 1938; 62: 421